ADP:EURONEXT PARISAeroports de Paris Analysis
Data as of 2026-03-11 - not real-time
$213.00
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
ADP is trading at $213, which sits below its 20‑day (≈215.5), 50‑day (≈237.4) and 200‑day (≈276.4) moving averages, signaling a short‑term bearish bias. The RSI of 38.6 hints at a modestly oversold condition, while the MACD histogram is positive (+1.77), suggesting a potential technical bounce. Volume has been trending down, and 30‑day volatility remains high at 32.7%, which together raise short‑term risk, although the stock’s beta of 0.58 points to lower systematic risk.
Fundamentally, ADP delivered a solid Q2 beat with 6% revenue growth, an 80‑bp EBIT margin expansion and an 11% rise in adjusted EPS, prompting management to lift its FY‑2026 EPS outlook to 9‑10% and announce an expanded share‑repurchase program. The company trades at a forward PE of 17.8, well under the industry average of 37.0, and offers a 3.13% dividend yield with a payout ratio near 60%. However, its DCF‑derived fair value of $149 is well below the current price, indicating that the market may be overvaluing the stock relative to intrinsic calculations, even as analysts target a mean price of $272.
Fundamentally, ADP delivered a solid Q2 beat with 6% revenue growth, an 80‑bp EBIT margin expansion and an 11% rise in adjusted EPS, prompting management to lift its FY‑2026 EPS outlook to 9‑10% and announce an expanded share‑repurchase program. The company trades at a forward PE of 17.8, well under the industry average of 37.0, and offers a 3.13% dividend yield with a payout ratio near 60%. However, its DCF‑derived fair value of $149 is well below the current price, indicating that the market may be overvaluing the stock relative to intrinsic calculations, even as analysts target a mean price of $272.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Price below key moving averages and bearish trend direction
- Decreasing volume and elevated short‑term volatility
- Strong recent earnings beat and dividend yield
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Raised FY‑2026 EPS outlook and expanding share‑repurchase program
- Forward PE well below industry average, indicating value upside
- Target price of $272 implies ~27% upside from current level
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- Sustainable dividend supported by solid cash flow and moderate leverage
- High ROE and recurring HCM revenue base provide durable earnings power
- DCF fair value gap suggests caution on price appreciation
Key Metrics & Analysis
Financial Health
Revenue Growth6.20%
Profit Margin19.96%
P/E Ratio20.5
ROE73.84%
ROA4.71%
Debt/Equity70.04
P/B Ratio13.4
Op. Cash Flow$4.7B
Free Cash Flow$3.5B
Industry P/E37.0
Technical Analysis
TrendBearish
RSI38.6
Support$203.26
Resistance$226.50
MA 20$215.48
MA 50$237.40
MA 200$276.35
MACDBullish
VolumeDecreasing
Fear & Greed Index78.16
Valuation
Fair Value$149.23
Target Price$272.00
Upside/Downside27.70%
GradeOvervalued
TypeBlend
Dividend Yield3.13%
Risk Assessment
Beta0.58
Volatility32.66%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.